Koch Disruptive Technologies led a $73 Series B round in Deepcell.

Koch Disruptive Technologies, a venture capital firm that invests in technologies to improve businesses and create new opportunities, led a $73 Series B round in Deepcell, a life science company pioneering AI-powered single cell classification and isolation for basic and translational research, with participation from Bridger Healthcare, Horizons Ventures, Casdin Capital, Andreessen Horowitz, Bow Capital, Jeff Dean, and Matt Mcllwain. “The new funding will help us to accelerate our growth, develop our platform, and take a major step toward full commercialization. The support we are receiving highlights the potential of Deepcell’s AI-powered single cell morphology analysis, and enables us to expand the team, transition to late-stage development and accelerate towards introducing our platform to a present and growing list of potential customers,” Maddison Masaeli, Deepcell CEO and Co-founder.